Detalles de la búsqueda
1.
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
Clin Gastroenterol Hepatol;
21(9): 2347-2358.e6, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36464141
2.
Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis.
Dig Dis Sci;
68(6): 2318-2332, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36773193
3.
Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study.
BMC Urol;
15: 31, 2015 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-25879460
4.
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Aliment Pharmacol Ther;
59(3): 393-408, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38010661
5.
Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data.
Inflamm Bowel Dis;
29(11): 1723-1729, 2023 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36790041
6.
Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results.
Inflamm Bowel Dis;
29(9): 1421-1430, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36645051
7.
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis.
Crohns Colitis 360;
5(2): otad009, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36998249
8.
Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
J Gastroenterol;
58(10): 990-1002, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37490069
9.
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
Lancet Gastroenterol Hepatol;
8(11): 976-989, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37683686
10.
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Am J Clin Dermatol;
19(3): 457, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29600394
11.
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Am J Clin Dermatol;
18(2): 273-280, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28074446
12.
Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.
Eur Urol;
67(1): 114-122, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25301757
13.
Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.
Nat Rev Urol;
11(4): 231-41, 2014 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24619381
Resultados
1 -
13
de 13
1
Próxima >
>>